KUALA LUMPUR, July 29 (Bernama) -- Subscription management platform Chargebee has announced its Summer 2022 Product Release.
The slate of new products and features is focused on enabling high-performing subscription businesses to monetise their existing customers and fend off the growing threats of a tumultuous economy, a Chargebee statement said. The overall challenge today is to manage cash flow processes by automating accounts receivables workflows, predict payment failure to minimise involuntary churn and increase customer retention and experiment with different packaging and pricing options. “We’ve spent months engaging with customers, learning the ins and outs of their businesses and working with them to determine what types of tools they want and need to face their current challenges head-on,” product management vice president John Pearce said. The software tools and solutions that form the centrepiece of its summer collection include Chargebee Retention, formerly Brightback, which along with Chargebee Receivables (numberz), and RevRec (RevLock), were acquired by Chargebee over the last 18 months, and represent Chargebee’s foray into becoming a multi-product company. Pearce said these products will help customers “to build and scale their businesses, even in these trying times.” Chargebee Retention allows businesses to focus on retaining customers they have at a time when both businesses and consumers have to evaluate everything in their portfolios and make difficult decisions, the statement said. Chargebee Receivables helps businesses improve their cash flow management processes by automating accounts receivable workflows, while Chargebee Entitlements helps go-to-market teams provide feature access to customers beyond their plan on the flip of a switch, which can be used to incentivise plan upgrades and free-to-paid conversions. The volatility of today’s market landscape calls for adaptability and being agile in ways businesses have not thought of previously, the statement said. More details at www.chargebee.com. -- BERNAMA
0 Comments
KUALA LUMPUR, July 29 (Bernama) -- Independent public accounting firm, Marcum Bernstein & Pinchuk LLP (MBP) has expanded its market reach with the opening of its new office in Marina Bay Financial Centre, Singapore.
With its strong base of experience auditing Chinese issuers listed in the United States market, MBP has expanded its client roster to include Indonesia, Singapore, Malaysia and other Southeast Asia (SEA) countries, said co-chair of MBP, Neil Pinchuk. “We continue to see strong demand for our services in China as companies navigate an evolving regulatory environment and need to sustain the confidence of international investors. “With this expansion, MBP seeks to set the standard for responsiveness and audit quality in the region,” he said in a statement today. The office will support its growing practice of SEA clients seeking to access global capital markets through an Initial Public Offering (IPO) or Special Purpose Acquisition Company (SPAC) merger. According to the statement, the firm’s expansion into Singapore was driven by the high demand for dedicated audit and advisory services for Asia-based businesses. The firm added that its managing director, Pearl Peng has relocated from Hong Kong to Singapore to support the expansion of MBP's Asia footprint. More details are available at www.marcumbp.com. -- BERNAMA The CDMO’s Milan facility provides lentiviral vector and autologous CD34+ cell-based drug products for clinical testing
SEATTLE, MILAN, July 29 (Bernama-GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Altheia Science, a gene therapy company pioneering cell and gene therapy strategies to treat autoimmune diseases and cancer. Through this partnership, Altheia Science will advance its development of autoimmunity treatments, focused on modulating PD-L1 expression in patients’ hematopoietic stem and progenitor cells, into clinical testing. AGC Biologics is performing drug product development at its Milan facility using lentiviral vector (LVV) and autologous CD34+ hematopoietic stem and progenitor cell systems. The cells will be transduced using a highly efficient ex vivo lentiviral material to encode the human PD-L1 DNA. “The AGC Biologics Milan site has a long-standing expertise in successfully developing stem cell-based gene therapies, from clinical testing up to commercialization,” said Paolo Rizzardi, Chief Executive Officer of Altheia Science. “We believe this partnership is key in supporting our gene therapy programs and making these innovative therapies available to patients." The AGC Biologics Milan facility has one of the strongest development and manufacturing track records in the global cell and gene industry, working with virtually any cell type and lentiviral, retroviral and adeno‐associated viral vectors. The site has 25 years of expertise, including manufacturing three commercial products, and teams of scientists with significant development and regulatory experience. The site was the first ex-vivo cell and gene therapy site approved in Europe for GMP manufacturing of clinical and commercial supplies. “We are pleased Altheia Science placed their trust in our cell therapy and viral vector services, and our Milan site, at this important stage in their product’s lifecycle,” notes JB Agnus, Chief Business Officer of AGC Biologics. “Our global Cell Therapy and Viral Vector services are powerful tools for partners creating life-changing treatments for patients. We pride ourselves on our ability to collaborate with cell and gene developers and work within their unique specifications and requirements.” AGC Biologics’ cell therapy services and viral vector capabilities leverage the latest technology and processes, including proprietary platforms developed to address the evolving advanced therapies industry. To learn more about the company and its complete list of biologics and cell and gene services, visit www.agcbio.com. About Altheia Science Altheia Science has been founded by Prof. Alessandra Biffi, MD, and Prof. Paolo Fiorina, MD, Ph.D., together with the investment company AurorA-TT (www.aurora-tt.com). Altheia Science develops pioneering cell & gene therapy strategies to treat autoimmune diseases and cancer. To learn more, visit www.altheiascience.com. About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,500 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. To learn more, visit www.agcbio.com. Attachment · AGC Biologics Signs Contract with Altheia Science Nick McDonald AGC Biologics 4254193555 [email protected] Source: AGC Biologics --BERNAMA KUALA LUMPUR, July 27 (Bernama) -- Enterprises in Malaysia and Singapore are embracing software-defined networking (SDN) to improve network integration, automation, orchestration and management, in a trend expected to continue for several years.
This is according to a new research report published by Information Services Group (ISG), a leading global technology research and advisory firm. The 2022 ISG Provider Lens Network — Software Defined Solutions and Services report for Singapore and Malaysia said companies in the region are adopting SDN so they can seamlessly add applications and network resources to meet business and user goals more efficiently and securely. “To remain competitive, enterprises need to become data-driven, with optimal connectivity, multi-cloud capability and end-to-end security,” said Deepraj Emmanuel, director of ISG Asia based in Singapore. “These requirements are creating huge opportunities for carriers and managed service providers operating in Singapore and Malaysia,” he said in a statement. Over the next five to 10 years, SDN will allow organisations to monitor workflows and segment networks from end to end, among other capabilities, the report said. Key features made possible by SDN include intent-based networks, rapid hotspot provisioning, edge computing and solutions powered by artificial intelligence and machine learning. The report also examines other aspects of the SDN’s emergence in Singapore and Malaysia, including the growing maturity of service providers and how they are helping enterprises enhance their performance with SDN. More details at www.isg-one.com. -- BERNAMA KUALA LUMPUR, July 26 (Bernama) -- In another move that delivers next-generation levels of performance to enterprise data centres, Kioxia Corporation has announced that its KIOXIA CM7 series enterprise NVMe™ SSDs are now shipping to select customers. Optimised for the needs of high-performance, highly efficient servers and storage, the KIOXIA CM7 series family is designed with PCIe® 5.0 technology in Enterprise and Datacenter Standard Form Factor (EDSFF) E3.S and 2.5-inch form factors. Having introduced the industry’s first EDSFF drives designed with PCIe 5.0 technology last year, the addition of the KIOXIA CM7 series family expands KIOXIA’s leadership position and allows OEM customers to deliver best-in-class sequential read 14 GB/s performance to end users. According to a statement, the EDSFF E3 family enables the next generation of SSDs with PCIe 5.0 technology and beyond to address future data centre architectures, while supporting a variety of new devices and applications. It provides improved airflow and thermals, signal integrity benefits, eliminates the need for LEDs on the drive carriers, and gives options for larger SSD capacity points. Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid-state drives (SSDs). -- BERNAMA |
Archives
April 2023
|